Presentation on ATH434 to American Academy of Neurology
Filed with ASX · · 2 pages · English
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Appendix 4C and Quarterly Update
- NASDAQ Temporary Relief
- NASDAQ Non-Compliance Notice Received
- Appendix 4C - quarterly
- Alterity receives a $4.8 million R&D Tax Incentive Refund
Later from Alterity Therapeutics
- Meeting with US FDA provides development path for ATH434
- Pause in Trading
- New data independently confirms safety profile of ATH434
- Preliminary Final Report
- Company update on Annual Report 2020
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics